Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is Chief of Clinical Trials, Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Centre Tom Powles is Director of Barts Cancer Centre, St Bartholomews Hospital and Professor or Genitourinary oncology, Queen Mary University of London
…
continue reading
1
Episode 364: 腎がんの最新の話題〜IO rechallengeと乳頭型腎がんの治療戦略〜
15:41
15:41
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
15:41
腎がんの最新の話題〜IO rechallengeと乳頭型腎がんの治療戦略〜
…
continue reading
1
Episode 363: 前立腺がんの最新の話題〜T cell directed therapyとradioligands〜
14:23
14:23
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
14:23
前立腺がんの最新の話題〜T cell directed therapyとradioligands〜
…
continue reading
1
Episode 362: 膀胱がんの最新の話題〜周術期薬物療法とADC〜
12:42
12:42
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
12:42
膀胱がんの最新の話題〜周術期薬物療法とADC〜
…
continue reading
1
Episode 361: The Role of Monotherapy AR Inhibition in Prostate Cancer
25:43
25:43
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
25:43
Betrand Tombal joins Brian and Tom to discuss the historic and current data for AR inhibition with monotherapy with AR blockers.
…
continue reading
1
Episode 360: The SUNRISE Program in Bladder Cancer
46:19
46:19
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
46:19
Christopher Cutie from J&J joins the show to discuss the SUNRISE bladder program with the gemcitabine-eluting pretzel across several NMIBC and MIBC states.
…
continue reading
1
Episode 359: #UromigosLive24 - IO after IO in RCC
40:41
40:41
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
40:41
The RCC panel at Uromigos Live 2024 discusses and debates this topic.
…
continue reading
1
Episode 358: Noticias del Dia 1 de Uromigos Live 2024 en Nashville
21:59
21:59
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
21:59
Eneste podcast cubrimos los temas de cáncer urotelial discutidos por los Uromigos. El impacto del estudio NIAGARA en utiliar quimio más inmunoterapia enneadyuvancia de Ca urotelial músculo invasor, el uso de pembrolizumab adyuvante después de los datos del estudio AMBASSADOR y la búsqueda de biomarcadores.…
…
continue reading
1
Episode 357: #UromigosLive24 - Peri-operative Therapy in Bladder Cancer
1:03:10
1:03:10
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
1:03:10
Tom leads a panel of Shilpa Gupta, Andrea Apolo, Kala Sridhar and Petros Grivas to discuss and debate this timely topic.
…
continue reading
1
Episode 356: #UromigosLive24 - Front-line Therapy in Papillary and Non-clear Cell RCC
26:22
26:22
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
26:22
Brian moderates the panel that discusses and debates TKI, vs Ipi/Nivo vs IO/TKI
…
continue reading
1
Episode 355: #UromigosLive24 - Radioligands in prostate cancer
54:23
54:23
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
54:23
The Uromigos Live 2024 panel discusses recent radioligand data including PEACE-3
…
continue reading
1
Episode 354: #UromigosLive24 - T cell directed therapy in prostate cancer
44:00
44:00
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
44:00
Brian hosts a panel at Uromigos Live 2024 in Nashville with Michael Morris, Tanya Dorff and Karen Autio
…
continue reading
1
Episode 353: #UromigosLive24 ADC session
53:28
53:28
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
53:28
Tom moderates a live panel of Kala Sridhar, Shilpa Gupta, Andrea Apolo and Petros Grivas on the emerging ADC data in bladder cancer
…
continue reading
1
Episode 352: ESMO 2024 - RCC and Bladder review
26:25
26:25
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
26:25
Tom and Brian finish discussing ESMO 2024 highlights. Even without a guest Tom still interrupts a lot.
…
continue reading
1
Episode 351: ESMO 2024 review part 1: prostate cancer
18:48
18:48
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
18:48
Silke joins us to discuss ESMO 2024 highlights, then the birds start singing....
…
continue reading
1
Episode 350: ESMO 2024 - NIAGARA
23:51
23:51
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
23:51
Fresh of the Presidential session address, Tom discusses his data with Petros commenting.
…
continue reading
1
Episode 349: ESMO 2024 - Uromigos Japan!!
30:56
30:56
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
30:56
Uromigos Japan with Yuji, Hiroshi and Nobu is formed and discuss Hiroshi's ESMO data.
…
continue reading
1
Episode 348: ESMO 2024 - UpFrontPSMA
33:52
33:52
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
33:52
Arun Azad describes this randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel vs. docetaxel in mHSPC
…
continue reading
1
Episode 347: ESMO 2024 - DV + Pembro in Urothelial Cancer
17:59
17:59
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
17:59
Matt Galsky describes his ESMO 2024 abstract of disitimab vedotiin + pembrlizumab in bladder cancer
…
continue reading
1
Episode 346: ESMO 2024 - PEACE-3: Enza/Radium-223 vs Enza in mCRPC
25:47
25:47
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
25:47
Silke Gillessen joins us to discuss her Presidential session from ESMO 2024
…
continue reading
1
Episode 345: ESMO 2024 - SUNNIFORECAST: Ipi/Nivo vs SOC in Non-clear Cell RCC
31:10
31:10
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
31:10
Lothar Bergmann describes this investigator-initiated trial of Ipi/Nivo vs SOC in Non-clear Cell RCC
…
continue reading
1
Episode 344: ESMO 2024 - NKT2152, a HIF inhibitor in RCC
22:32
22:32
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
22:32
Brad McGregor joins Brian and Tom to discuss a new HIF inhibitor, NKT2152, and preliminary data in RCC
…
continue reading
1
Episode 343: ESMO 2024 - TiNivo-2 Trial
31:23
31:23
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
31:23
Katy Beckermann discusses the TiNivo-2 study presented at ESMO 2024.
…
continue reading
1
Episode 342: ESMO 2024 Preview with Silke Gillessen
32:24
32:24
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
32:24
Silke joins Brian and Tom to discuss upcoming data in prostate, bladder and kidney cancer in Barcelona at ESMO 2024
…
continue reading
1
Episode 341: Hormone Resistance in Prostate Cancer
33:05
33:05
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
33:05
Nima Sharifi joins Brian and Tom to discuss mechanisms of resistance to hormone therapy in prostate cancer
…
continue reading
1
Episode 340: Cancer Immunity Cycle Update
41:50
41:50
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
41:50
Ira Mellman delves into the update of this classic paper and the components of an effective anti-tumor immune response.
…
continue reading
1
Episode 339: Tres Uramigas analizan lineamientos de ESMO para GU
18:37
18:37
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
18:37
María, Christina y Elena analizan los cambios recientes en las directrices de la ESMO en el cáncer de riñón, vejiga y próstata.
…
continue reading
1
Episode 338: RCC: Debulking Nephrectomy, Adjuvant Therapy Future and More
25:39
25:39
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
25:39
Naomi Haas joins Tom and Brian in New York City at the World GU Conference to discuss several RCC topics
…
continue reading
1
Episode 337: Updated NCCN Guidelines in RCC
42:38
42:38
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
42:38
Eric Jonasch, Co-Chair of the NCCN RCC Guidelines, gives insight into the process of guideline modification and discusses updates in adjuvant, front-line and refractory RCC
…
continue reading
1
Episode 336: Which patients are not suitable for 1st line EVP in bladder cancer
35:35
35:35
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
35:35
Jonathan Rosenberg and a surprise guest discuss comorbidities and treatment-related side effects.
…
continue reading
1
Episode 335: Novel immune therapies for renal cancer
37:31
37:31
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
37:31
David Braun divides immune therapies into four groups and describes how novel treatments and targets work. Tom and Brian are both excited and, at times, sceptical.
…
continue reading
1
Episodio 334 en español: Tres Uramigas ASCO 2024
36:33
36:33
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
36:33
Escuche nuestro primer podcast sobre los aspectos más destacados de ASCO en cáncer de vejiga, riñón y próstata
…
continue reading
1
Episode 333: The Uromigos Cup - The Netherlands
26:20
26:20
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
26:20
Axel Bex, Christian Blank, Laura Mertens and Micheil Van der Heijden answer a range of relevant and sometimes irrelevant questions
…
continue reading
1
Episode 332: The Uromigos Cup - Germany's Entry
35:55
35:55
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
35:55
Viktor Gruenwald, Boris Hadaschik and Gunhild Von Amsberg answer questions around GU cancer and German football
…
continue reading
1
Episode 331: AUA 2024 NMIBC Highlights
33:56
33:56
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
33:56
Aditya Bagrodia describes three new drugs/studies in NMIBC.
…
continue reading
1
Episode 330: ASCO 2024 Highlights
52:47
52:47
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
52:47
Silke Gillessen joins Tom and Brian, who give their opinion on the data and new 'Take Home Message' format.
…
continue reading
1
Episode 329: Japan in the Uromigos Cup qualifying round
30:48
30:48
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
30:48
Nobuaki Matsubara, Hiroshi Kitamura and Yuji Miura battle through the sometimes ridiculous questions set by Tom and Brian.
…
continue reading
1
Episode 328 ASCO24: Emergency podcast - what the NADINA trial means for preoperative GU cancer studies
26:32
26:32
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
26:32
David McDermott discusses the adjuvant vs neoadjuvant immune therapy trial and its wider implications.
…
continue reading
1
Episode 327 ASCO24: CM901 and EV302 Efficacy and QOL Updates
24:02
24:02
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
24:02
Guru Sonpavde describes the efficacy of chemotherapy with nivolumab in lymph node only 1st line UC patients. Tom describes the QOL data for EV pembro.
…
continue reading
1
Episode 326 ASCO24: KIM-1 in Renal Cancer
18:08
18:08
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
18:08
Laurence Albiges discusses this circulating biomarker which may be predictive and prognostic.
…
continue reading
1
Episode 325 ASCO24: KN426 and the CLEAR trial - tissue based biomarkers for kidney cancer
33:44
33:44
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
33:44
Toni Choueiri and Brian describe similarities and differences in the biomarker findings of these two trials. Debate about the value and future of this approach breaks out.
…
continue reading
1
Episode 324 ASCO24: SURE1 neoadjuvant sacituzumab govitecan in UC
20:43
20:43
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
20:43
Andrea Necchi gives us the lowdown of efficacy and toxicity of this combination.
…
continue reading
1
Episode 323 ASCO24: TDXD in Bladder Cancer
29:47
29:47
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
29:47
Jonathan Rosenberg gets to grips with the data available for the bladder cohort from the TDXD Destiny pan-tumour cohort.
…
continue reading
1
Episode 322 ASCO24: The role of ctDNA in the TheraP trial (LuPSMA vs cabazitaxel in CRPC)
22:16
22:16
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
22:16
Alex Wyatt describes the predictive resistance of ctDNA fraction at baseline in predicting outcome.
…
continue reading
1
Episode 321 ASCO24: CHAARTED-2 in prostate cancer - is the sequel as good as the original?
23:25
23:25
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
23:25
Christos Kyriakopoulos describes the outcome of this study, where cabazitaxel with abiraterone as combined with abiraterone alone in docetaxel refractory CRPC.
…
continue reading
1
Episode 320: Team Canada's entry for the Uromigos Cup
23:30
23:30
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
23:30
Danny Heng, Christian Kollmannsberger and Kala Sridhar answer questions in an attempt to get to Nashville and take on LA to win the Uromigos Cup.
…
continue reading
1
Episode 319: ASCO 2024: A Preview of GU Data
33:49
33:49
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
33:49
What to see at the ASCO 2024 Annual Meeting, with Silke Gillessen.
…
continue reading
1
Episode 318: The Lancet Commission on prostate cancer: planning for a surge in cases
31:59
31:59
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
31:59
Nick James discusses this paper, which covers broad issues in prostate cancer - including diagnosis and treatment with a focus on the future.
…
continue reading
1
Episode 317: AUA 2024 Preview with the AUA Secretary
22:16
22:16
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
22:16
David Penson discusses highlights for the upcoming meeting. He articulates his excitement around the NMIBC data.
…
continue reading
1
Episode 316: APCCC 2024 Summary with Silke Gillessen
41:11
41:11
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
41:11
Silke covers key aspects of the meeting, including surgery vs RT, genetic and somatic testing, PSMA imaging and 1st line triplet therapy.
…
continue reading
1
Episode 315: APCCC 2024 Quickfire - Bone health, hot flashes and gynecomastia in prostate cancer
18:17
18:17
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
18:17
Chris Sweeney is joined by Matt Smith, Anthony Joshua and Lisa Horvath to discuss the management of these complex issues in advanced prostate cancer.
…
continue reading